Related Experiment Videos
New therapies for chronic hepatitis B
1Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda 20892, USA.
Journal of Viral Hepatitis
|January 1, 1997
Summary
New nucleoside antivirals like lamivudine and famciclovir show promise for treating chronic hepatitis B, offering improved viral inhibition and potential long-term benefits beyond current therapies.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis B (CHB) treatment options are limited, with interferon-alpha benefiting only one-third of patients.
- Emerging therapies include antiviral chemotherapy, immunomodulation, and gene therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of new nucleoside antiviral therapies for chronic hepatitis B.
- To assess the potential of lamivudine and famciclovir for sustained viral inhibition and liver disease improvement.
Main Methods:
- Review of current therapeutic approaches for CHB.
- Focus on the development and ongoing clinical trials of nucleoside antivirals.
Main Results:
- Nucleoside antivirals lamivudine and famciclovir demonstrate oral absorption and significant inhibition of hepatitis B virus.
- These agents can lead to loss of hepatitis B e antigen and improved liver enzymes in some patients.
Conclusions:
- Lamivudine and famciclovir represent promising immediate therapeutic options for CHB.
- Long-term controlled trials are essential to confirm the safety and sustained efficacy of these nucleoside antivirals in managing CHB.